Gene Information
Gene symbol: BCL2
Gene name: B-cell CLL/lymphoma 2
HGNC ID: 990
Synonyms: Bcl-2, PPP1R50
Related Genes
| # | Gene Symbol | Number of hits |
| 1 | BAX | 1 hits |
| 2 | BCL2L1 | 1 hits |
| 3 | BRCA1 | 1 hits |
| 4 | BRCA2 | 1 hits |
| 5 | CDKN1A | 1 hits |
| 6 | CTSD | 1 hits |
| 7 | EGFR | 1 hits |
| 8 | EP300 | 1 hits |
| 9 | ERBB2 | 1 hits |
| 10 | MDM2 | 1 hits |
| 11 | PSMD9 | 1 hits |
| 12 | TP53 | 1 hits |
Related Sentences
| # | PMID | Sentence |
| 1 | 9378159 | Highly expressed oncogenes such as bcl-2, HER2/neu and others or mutated suppressor genes such as p53 or BRCA1 have been characterised as hereditary susceptibility genes leading to syndromes such as breast/ovarian cancer syndrome, Li-Fraumeni and others. |
| 2 | 9378159 | Furthermore efflux-genes such as MDR-1 or MRP can be circumvented, suicide-genes can be employed which can facilitate sensitivity by encoding enzymes capable of converting inactive forms of a drug into toxic antimetabolites and immunotherapy can be achieved, by transfection of tumour cells with adenoviral vectors encoding immunomodulators such as IL-2 or MHC molecules. |
| 3 | 9581822 | To characterize the biological features of breast cancer associated with germ-line mutations in BRCA1 and BRCA2, invasive tumors were studied from 58 Jewish women ascertained through studies of early-onset breast cancer. |
| 4 | 9581822 | All women were tested for the BRCA1 founder mutations 187delAG (commonly known as 185delAG) and 5385insC (commonly known as 5382insC) and the BRCA2 founder mutation 6174delT. |
| 5 | 9581822 | There were no differences between the two groups in the frequency of expression of epidermal growth factor receptor, cathepsin D, bcl-2, p27, p53, or cyclin D. |
| 6 | 9662340 | As compared with parental cells and vector transfected clones, wtBRCA1 clones exhibited: (1) a slightly decreased proliferation rate (doubling time = 25 h as compared with 22 h for control cells); (2) a (3-6)-fold increase in sensitivity to chemotherapy drugs (adriamycin, camptothecin, and taxol); (3) increased susceptibility to drug-induced apoptosis; (4) reduced repair of single-strand DNA strand breaks; and (5) alterations in expression of key cellular regulatory proteins (including BRCA2, p300, Mdm-2, p21(WAF1/CIP1), Bcl-2 and Bax). |
| 7 | 9674697 | Western blotting analysis revealed that pre-treatment of MDA-MB-453 cells with SF inhibited the ADR-induced decreases in the levels of Bcl-XL, an anti-apoptotic protein related to Bcl-2; and the dose-response and time course characteristics for SF-mediated increases in the Bcl-XL protein levels of ADR-treated cells were consistent with the degrees of protection against apoptosis observed under the same conditions. |
| 8 | 9674697 | In contrast to Bcl-XL, SF blocked ADR-induced increases in c-Myc and inhibited the expression of p21WAF1/CIP1 and of the BRCA1 protein in MDA-MB-453 cells. |